Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Epigenetic control over cell-intrinsic immune response antagonizes self-renewal in acute myeloid leukemia.
Felipe Fumero E, Walter C, Frenz JM, Seifert FC, Alla V, Hennig T, Angenendt L, Hartmann W, Wolf S, Serve H, Oellerich T, Lenz G, Müller-Tidow C, Schliemann C, Huber O, Dugas M, Mann M, Jayavelu AK, Mikesch JH, Arteaga MF. Felipe Fumero E, et al. Among authors: angenendt l. Blood. 2024 Mar 8:blood.2023021640. doi: 10.1182/blood.2023021640. Online ahead of print. Blood. 2024. PMID: 38457355 Free article.
Prevalence and clinical impact of CD56 and T-cell marker expression in acute myeloid leukaemia: A single-centre retrospective analysis.
Shaforostova I, Call S, Evers G, Reicherts C, Angenendt L, Stelljes M, Berdel WE, Pohlmann A, Mikesch JH, Rosenbauer F, Lenz G, Schliemann C, Wethmar K. Shaforostova I, et al. Among authors: angenendt l. EJHaem. 2023 Nov 22;5(1):93-104. doi: 10.1002/jha2.827. eCollection 2024 Feb. EJHaem. 2023. PMID: 38406551 Free PMC article.
Clonally resolved single-cell multi-omics identifies routes of cellular differentiation in acute myeloid leukemia.
Beneyto-Calabuig S, Merbach AK, Kniffka JA, Antes M, Szu-Tu C, Rohde C, Waclawiczek A, Stelmach P, Gräßle S, Pervan P, Janssen M, Landry JJM, Benes V, Jauch A, Brough M, Bauer M, Besenbeck B, Felden J, Bäumer S, Hundemer M, Sauer T, Pabst C, Wickenhauser C, Angenendt L, Schliemann C, Trumpp A, Haas S, Scherer M, Raffel S, Müller-Tidow C, Velten L. Beneyto-Calabuig S, et al. Among authors: angenendt l. Cell Stem Cell. 2023 May 4;30(5):706-721.e8. doi: 10.1016/j.stem.2023.04.001. Epub 2023 Apr 24. Cell Stem Cell. 2023. PMID: 37098346 Free article.
A randomized phase 2 trial of nintedanib and low-dose cytarabine in elderly patients with acute myeloid leukemia ineligible for intensive chemotherapy.
Berdel AF, Koch R, Gerss J, Hentrich M, Peceny R, Bartscht T, Steffen B, Bischoff M, Spiekermann K, Angenendt L, Mikesch JH, Kewitz T, Butterfass-Bahloul T, Serve H, Lenz G, Berdel WE, Krug U, Schliemann C. Berdel AF, et al. Among authors: angenendt l. Ann Hematol. 2023 Jan;102(1):63-72. doi: 10.1007/s00277-022-05025-0. Epub 2022 Nov 18. Ann Hematol. 2023. PMID: 36399194 Free PMC article. Clinical Trial.
Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse.
Berdel AF, Ruhnke L, Angenendt L, Wermke M, Röllig C, Mikesch JH, Scheller A, Hemmerle T, Matasci M, Wethmar K, Kessler T, Gerwing M, Hescheler D, Schäfers M, Hartmann W, Altvater B, Rossig C, Bornhäuser M, Lenz G, Stelljes M, Rueter B, Neri D, Berdel WE, Schliemann C. Berdel AF, et al. Among authors: angenendt l. Blood Adv. 2022 Jun 28;6(12):3684-3696. doi: 10.1182/bloodadvances.2021006909. Blood Adv. 2022. PMID: 35468621 Free PMC article. Clinical Trial.
39 results